Picture EBD Group ChinaBio Partnering Forum 2022 650x100
Employment/Membership › Details

Leo Pharma–Bourdon C: management, Leo Pharma 202204– CEO before Orphazyme + Amgen + Alexion


Period Period 2022-04-01
Organisations Organisation Leo Pharma A/S
  Group Leo Pharma (Group)
  Organisation 2 Orphazyme A/S (Nasdaq Copenhagen: ORPHA.CO)
  Group Orphazyme (Group)
Products Product dermatic
  Product 2 DRUGS, ORPHAN
Person Person Bourdon, Christophe (Leo Pharma 202204– CEO before Orphazyme + Amgen + Alexion)

Leo Pharma A/S. (1/31/22). "Press Release: Leo Pharma Appoints Christophe Bourdon as New CEO". Ballerup.

LEO Pharma today announced the appointment of Christophe Bourdon as new Chief Executive Officer of the company, effective April 1, 2022. Christophe Bourdon joins from Orphazyme A/S where he has held the position as CEO since April 2021, following significant global leadership roles in both Amgen and Alexion.

LEO Pharma is taking significant steps to transform the company to become a competitive, global player in the growing dermatology market, successfully launch a global product portfolio and prepare the company for a public listing (IPO).

To lead this, the Board of Directors of LEO Pharma today announced the appointment of Christophe Bourdon as new CEO as of April 1, 2022.

“I am thrilled that Christophe Bourdon joins LEO Pharma as new CEO. Christophe Bourdon is an international and accomplished leader. I am confident that he is the right person to lead LEO Pharma’s transformation towards becoming a publicly listed leader in medical dermatology. The Board of Directors is looking forward to working closely with Christophe Bourdon and the Global Leadership Team on the next chapters of LEO Pharma’s growth journey,” said Chairman of the Board of Directors, Jesper Brandgaard.

Christophe Bourdon will join from a role as CEO of Orphazyme A/S. His previous roles include Senior Vice President, General Manager, U.S. Oncology Business, at US biotech Amgen Inc. where he also led commercialization planning of top-selling drugs on the global market. Prior to Amgen, Christophe Bourdon was Senior Vice President of Europe, Middle East, Africa, and Canada at Alexion as the company launched two breakthrough ultra-orphan drugs and negotiated payor access across UK, Germany, France, Italy, and Canada. Christophe Bourdon holds an MBA from IMD Business School (Switzerland) and a BA from ISG (France).

“I am excited to join LEO Pharma and bring my competences and experience into play as LEO Pharma goes through the next phases of its transformation. The company’s strong heritage appeals to me as well as the unique profile in medical dermatology. LEO Pharma has a huge potential for growth and for making a difference for people who need more treatment options for their skin conditions,” said Christophe Bourdon.

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10.133 billion.


Karen Frost
Global Communications, Public Affairs & Sustainability
Tel: +45 3166 1567

Record changed: 2022-03-16


Picture [iito] [LSE] Business Portal 650x200px

More documents for Leo Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] [LSE] Business Portal 650x300px

» top